Regen BioPharma Inc (RGBP)

[cvinvestor]

Progress.
No, it's not the rocket to the moon, but in context it means legitimate work and real IP with real patents are being built up which in the long term will add value and PPS to the company.

There are those that deny the legitimacy of the research and the scientists. Each of these filed patents are related to the work and targeted research of RGBP. One isn't for a forklift and the other for a child's toy etc. That means each application that is validated validates the research and IP of both the scientists and the company as a whole.

What if RGBP got FDA approval tomorrow for a clinical trial of a cure that while innovative, wasn't patent protected. Yes, we could all rejoice and sell our shares and then go elsewhere, since any success could be duplicated by much larger companies with much larger resources.

Instead, we don't have a rocket launch, but a much stronger and larger rocketship is quietly being built on a side launch pad while HemaX awaits its countdown.

The patent will also cover screening for small molecules that can turn-on the nuclear receptor. These molecules can be used for expansion of stem cells for expansion of cord-blood in the context of bone marrow transplants. Currently, it is estimated that 15,000 patients are in need of a stem cell transplant every year. However, 40% of patients cannot be adequately matched with a bone marrow donor. Cord blood stem cell transplants offers hope to these patients since the matching requirement for cord blood is much less stringent than for bone marrow stem cell transplants. Nevertheless, the number of cord blood transplants performed is constrained by the limited number of cells obtained from a single cord. The ability to expand cord blood cells for bone marrow transplantation may provide life-saving therapy for patients with fatal blood disorders like leukemia, sickle cell anemia, lymphoma, and immune system disorders.

I see this as potential revenue stream for licensing to companies whose research is not directly in competition to RGBP. It also adds potentially large value to any buyout consideration.

Lest we forget, the Ichims have sold their IP to RGBP under a 3 year contract, after which they have no guarantees from Koos - talk about risk. They have more invested in this company than any of us and their goal is to cure leukemia in their lifetime in memory of their mother.

Seems everything being done and being filed has a purpose that we may only see in the end. We are stuck on HemaX FDA approval (and there is reason), but all these other pieces will provide value once RGBP gets beyond its past of delays... 2015 is the year of hope.